TIE2 Pathway

An endothelial receptor tyrosine kinase that maintains vascular integrity. Long considered “undruggable.” Discussed by Anthony Adamis at Session VII.

Biology

• Ang-1 activates TIE2 → stable endothelial monolayer, pericyte coverage, no inflammation
• Ang-2 blocks TIE2 activation → in the presence of VEGF, drives leakage and neovascularization

Why It Was “Undruggable”

TIE2 requires specific receptor clustering for activation — simple agonist antibodies couldn’t induce the right geometry. Young Kwon’s laboratory in South Korea engineered a tetravalent antibody that solved the clustering problem.

Drugs

• Faricimab (Vabysmo) — Adamis’s bispecific blocking VEGF + Ang-2; incremental improvement (3–4 month durability) but limited by patients’ own Ang-1 levels
• Tiespectus — direct TIE2 agonist + VEGF inhibition; >95% complete fluid resolution within one week (Phase 3 in neovascular AMD)

Significance

TIE2 agonism represents the shift from suppression to repair — the theme of Session VII. Rather than blocking pathology (VEGF), it activates the endogenous repair pathway.